DARE — Dare Bioscience, Inc.

Summary of Daré Bioscience Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash and Cash Equivalents: Approximately $23 million.
• Working Capital: Approximately $3.8 million.
• Net Proceeds from Stock Sales: About $18.7 million.
• Grant Payments Received: Total of $7.3 million.
• General & Administrative Expenses: $2.5 million (up from $2 million in Q3 2024).
• Research & Development Expenses: $1.2 million (down 56% from $2.7 million in Q3 2024), primarily due to nondilutive funding and reduced manufacturing costs.

2. Strategic Updates and Business Highlights

• Dual Path Strategy: Daré is focusing on commercializing proprietary formulations via 503B compounding while pursuing FDA approvals.
• DARE to PLAY Sildenafil Cream: Expected to launch through a 503B outsourcing facility by December 2025, marking a significant milestone in women's sexual health.
• Clinical Pipeline: Advancements in programs targeting contraception (Ovaprene), HPV (DARE-HPV), and menopause (DARE to RECLAIM).
• DARE to RESTORE: Planned launch of vaginal probiotic products in Q1 2026.
• Partnerships: Collaborations with Medvantx for pharmacy services and logistics, and Rosy Wellness to enhance product awareness.

3. Forward Guidance and Outlook

• Revenue Generation: Initial revenue expected from DARE to PLAY in Q4 2025.
• Future Products: DARE to RECLAIM (hormone therapy ring) anticipated in early 2027, with both 503B compounding and FDA approval pathways being pursued.
• Clinical Trials: Continued focus on grant-funded programs with expected completion of Ovaprene enrollment in 2026.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: Ongoing discussions with the FDA regarding the approval pathways for various products, which could impact timelines.
• Market Competition: The need for broader partnerships and marketing strategies to effectively penetrate the women's health market.
• Funding Limitations: Current limitations on the use of the ATM (at-the-market) program due to market cap restrictions.

5. Notable Q&A Insights

• FDA Guidance on Hormone Therapy: Positive feedback on recent FDA changes regarding hormone replacement therapy, which could benefit DARE to RECLAIM.
• Partnerships for Awareness: Emphasis on the need for broader partnerships to increase awareness and accessibility of DARE to PLAY.
• R&D Prioritization: Focus on advancing products with clear paths to market, particularly those supported by grant funding, while evaluating additional R&D investments carefully.

Overall, Daré Bioscience is positioned for growth with a strong pipeline and strategic initiatives aimed at addressing women's health needs, despite facing regulatory and market challenges.